Protein aggregation in neurodegenerative diseases: Insights from computational analyses

Current Bioinformatics

Volumn 7, Issue 1, 2012, Pages 87-95

  Sarkar, Anita ^a,b   Kumar, Sonu ^a,c   Grover, Abhinav ^a   Sundar, Durai ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY DELHI   (India)

^b CNRS   (France)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Aggregation propensity; Amyloid; Computational prediction; Fibrillization; Mutants; Neurodegenerative diseases; Parkinson's disease; Protein aggregation; Protein misfolding; Synuclein

Indexed keywords

DISEASE CONTROL; GLYCOPROTEINS; NUCLEIC ACIDS; PROTEINS; SOLUBILITY;

AGGREGATION PROPENSITY; AMYLOID; COMPUTATIONAL PREDICTIONS; FIBRILLIZATION; MUTANT; PARKINSON'S DISEASE; PROTEIN AGGREGATION; PROTEIN MISFOLDING; SYNUCLEIN; Α-SYNUCLEIN;

NEURODEGENERATIVE DISEASES;

ALPHA SYNUCLEIN; AMYLIN; AMYLOID; AMYLOID BETA PROTEIN; APOLIPOPROTEIN A1; ATRIAL NATRIURETIC FACTOR; BETA 2 MICROGLOBULIN; CALCITONIN; COPPER ZINC SUPEROXIDE DISMUTASE; CYSTATIN; GELSOLIN; HUNTINGTIN; LYSOZYME; PREALBUMIN; PRION PROTEIN; PROLACTIN; SERUM AMYLOID A; TAU PROTEIN;

ALZHEIMER DISEASE; AMINO ACID SUBSTITUTION; AMYLOIDOSIS; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; ATHEROSCLEROSIS; CYTOTOXICITY; DEGENERATIVE DISEASE; DIFFUSE LEWY BODY DISEASE; ENDOPLASMIC RETICULUM; FAMILIAL AMYLOID POLYNEUROPATHY; FRONTOTEMPORAL DEMENTIA; HEART ARRHYTHMIA; HUMAN; HUNTINGTON CHOREA; HYDROPHOBICITY; INTERNET; MATHEMATICAL ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PH; PICK PRESENILE DEMENTIA; PRION; PRION DISEASE; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROLACTINOMA; PROTEIN AGGREGATION; PROTEIN FOLDING; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; RHEUMATOID ARTHRITIS; SHY DRAGER SYNDROME; SPINOCEREBELLAR DEGENERATION; TEMPERATURE; THYROID MEDULLARY CARCINOMA; VASCULAR AMYLOIDOSIS;

PYRONIA TITHONUS;

EID: 84863117217     PISSN: 15748936     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489312799304495     Document Type: Article

References (91)

1. Otzen DE, Pedersen JS, Christensen G. Modulation of S6 fibrillation by unfolding rates and gatekeeper residues. J Mol Biol 2004; 341: 575-88.
2. Rousseau F, Reumers J, Maurer-Stroh S, Schymkowitz J. Protein Sequences Encode Safeguards Against Aggregation. Hum Mutat 2009; 30: 431-7.
3. Ross CA, Poirier MA. title typecontributorProtein aggregation and neurodegenerative disease/title. Nat Med 2004; 10: S10-S7.
4. Aguzzi A, O'Connor T. Protein aggregation diseases: pathogenicity and therapeutic perspectives. Nat Rev Drug Discov 2010; 9: 237-48.
5. Murphy RM. Kinetics of amyloid formation and membrane interaction with amyloidogenic proteins. Bba-Biomembranes 2007; 1768: 1923-34.
6. Bukau B, Tyedmers J, Mogk A. Cellular strategies for controlling protein aggregation. Nat Rev Mol Cell Bio 2010; 11: 777-88.
7. Frieden C. Protein aggregation processes: In search of the mechanism. Protein Sci 2007; 16: 2334-44.
8. Chiti F, Taddei N, Baroni F, et al. Kinetic partitioning of protein folding and aggregation. Nat Struct Biol 2002; 9: 137-43.
9. Bousset L, Thomson NH, Radford SE, Melki R. The yeast prion Ure2p retains its native alpha-helical conformation upon assembly into protein fibrils in vitro. Embo J 2002; 21: 2903-11.
10. Rousseau F, Schymkowitz JWH, Wilkinson HR, Itzhaki LS. Three-dimensional domain swapping in p13suc1 occurs in the unfolded state and is controlled by conserved proline residues. P Natl Acad Sci USA 2001; 98: 5596-601.
11. Silow M, Oliveberg M. Transient aggregates in protein folding are easily mistaken for folding intermediates. P Natl Acad Sci USA 1997; 94: 6084-6.
12. Liu Y, Eisenberg D. 3D domain swapping: As domains continue to swap. Protein Sci 2002; 11: 1285-99.
13. Liu Y, Gotte G, Libonati M, Eisenberg D. Structures of the two 3D domain-swapped RNase A trimers. Protein Sci 2002; 11: 371-80.
14. Dobson CM. Principles of protein folding, misfolding and aggregation. Semin Cell Dev Biol 2004; 15: 3-16.
15. Bucciantini M, Giannoni E, Chiti F, et al. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 2002; 416: 507-11.
16. Kayed R, Head E, Thompson JL, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003; 300: 486-9.
17. O'Nuallain B, Wetzel R. Conformational Abs recognizing a generic amyloid fibril epitope. P Natl Acad Sci USA 2002; 99: 1485-90.
18. Anderluh G, Gutierrez-Aguirre I, Rabzelj S, et al. Interaction of human stefin B in the prefibrillar oligomeric form with membranes. Correlation with cellular toxicity. Febs J 2005; 272: 3042-51.
19. Si K, Lindquist S, Kandel ER. A neuronal isoform of the Aplysia CPEB has prion-like properties. Cell 2003; 115: 879-91.
20. Fowler DM, Koulov AV, Alory-Jost C, Marks MS, Balch WE, Kelly JW. Functional amyloid formation within mammalian tissue. Plos Biology 2006; 4: 100-7.
21. Beal MF, Lang AE, Ludolph AC. Neurodegenerative diseases: neurobiology, pathogenesis, and therapeutics: Cambridge University Press; 2005.
22. Spillantini MG, Schmidt ML, Lee VMY, Trojanowski JQ, Jakes R, Goedert M. alpha-synuclein in Lewy bodies. Nature 1997; 388: 839-40.
23. Cookson MR. The biochemistry of Parkinson's disease. Annu Rev Biochem 2005; 74: 29-52.
24. Buxbaum JN. Diseases of protein conformation: what do in vitro experiments tell us about in vivo diseases? Trends Biochem Sci 2003; 28: 585-92.
25. Uversky VN. Protein folding revisited. A polypeptide chain at the folding-misfolding-nonfolding cross-roads: which way to go? Cell Mol Life Sci 2003; 60: 1852-71.
26. Kelly JW. Towards an understanding of amyloidogenesis. Nat Struct Biol 2002; 9: 323-5.
27. Zerovnik E. Amyloid-fibril formation. Proposed mechanisms and relevance to conformational disease. Eur J Biochem 2002; 269: 3362-71.
28. Serio TR, Cashikar AG, Kowal AS, et al. Nucleated conformational conversion and the replication of conformational information by a prion determinant. Science 2000; 289: 1317-21.
29. Pallitto MM, Murphy RM. A mathematical model of the kinetics of beta-amyloid fibril growth from the denatured state. Biophys J 2001; 81: 1805-22.
30. Molinari M, Helenius A. Chaperone selection during glycoprotein translocation into the endoplasmic reticulum. Science 2000; 288: 331-3.
31. Bertolotti A, Zhang YH, Hendershot LM, Harding HP, Ron D. Dynamic interaction of BiP and ER stress transducers in the unfolded-protein response. Nat Cell Biol 2000; 2: 326-32.
32. Rajan RS, Illing ME, Bence NF, Kopito RR. Specificity in intracellular protein aggregation and inclusion body formation. P Natl Acad Sci USA 2001; 98: 13060-5.
33. Jaroniec CP, MacPhee CE, Bajaj VS, McMahon MT, Dobson CM, Griffin RG. High-resolution molecular structure of a peptide in an amyloid fibril determined by magic angle spinning NMR spectroscopy. P Natl Acad Sci USA 2004; 101: 711-6.
34. de la Paz ML, Lacroix E, Ramirez-Alvarado M, Serrano L. Computer-aided design of beta-sheet peptides. J Mol Biol 2001; 312: 229-46.
35. Nelson R, Sawaya MR, Balbirnie M, et al. Structure of the cross-beta spine of amyloid-like fibrils. Nature 2005; 435: 773-8.
36. Makin OS, Atkins E, Sikorski P, Johansson J, Serpell LC. Molecular basis for amyloid fibril formation and stability. P Natl Acad Sci USA 2005; 102: 315-20.
37. Koo EH, Lansbury PT, Kelly JW. Amyloid diseases: Abnormal protein aggregation in neurodegeneration. P Natl Acad Sci USA 1999; 96: 9989-90.
38. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997; 276: 2045-7.
39. Kruger R, Kuhn W, Muller T, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 1998; 18: 106-8.
40. Zarranz JJ, Alegre J, Gomez-Esteban JC, et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 2004; 55: 164-73.
41. Cookson MR. alpha-Synuclein and neuronal cell death. Mol Neurodegener 2009; 4.
42. Chiti F, Calamai M, Taddei N, Stefani M, Ramponi G, Dobson CM. Studies of the aggregation of mutant proteins in vitro provide insights into the genetics of amyloid diseases. P Natl Acad Sci USA 2002; 99: 16419-26.
43. Chiti F, Stefani M, Taddei N, Ramponi G, Dobson CM. Rationalization of the effects of mutations on peptide and protein aggregation rates. Nature 2003; 424: 805-8.
44. Dobson CM. The structural basis of protein folding and its links with human disease. Philos T Roy Soc B 2001; 356: 133-45.
45. Dobson CM. Protein-misfolding diseases: Getting out of shape. Nature 2002; 418: 729-30.
46. Kallberg Y, Gustafsson M, Persson B, Thyberg J, Johansson J. Prediction of amyloid fibril-forming proteins. J Biol Chem 2001; 276: 12945-50.
47. Sharon R, Bar-Joseph I, Frosch MP, Walsh DM, Hamilton JA, Selkoe DJ. The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron 2003; 37: 583-95.
48. Ulmer TS, Bax A. Comparison of structure and dynamics of micelle-bound human alpha-synuclein and Parkinson disease variants. J Biol Chem 2005; 280: 43179-87.
49. Vilar M, Chou HT, Luhrs T, et al. The fold of alpha-synuclein fibrils. P Natl Acad Sci USA 2008; 105: 8637-42.
50. Bradley P, Cowen L, Menke M, King J, Berger B. BETAWRAP: Successful prediction of parallel beta-helices from primary sequence reveals an association with many microbial pathogens. P Natl Acad Sci USA 2001; 98: 14819-24.
51. Fernandez-Escamilla AM, Rousseau F, Schymkowitz J, Serrano L. Prediction of sequence-dependent and mutational effects on the aggregation of peptides and proteins. Nat Biotechnol 2004; 22: 1302-6.
52. Cheng J, Baldi P. Three-stage prediction of protein beta-sheets by neural networks, alignments and graph algorithms. Bioinformatics 2005; 21 Suppl 1: 75-84.
53. Pawar AP, DuBay KF, Zurdo J, Chiti F, Vendruscolo M, Dobson CM. Prediction of aggregation-prone and aggregation-susceptible regions in proteins associated with neurodegenerative diseases. J Mol Biol 2005; 350: 379-92.
54. Trovato A, Seno F, Tosatto SC. The PASTA server for protein aggregation prediction. Protein Eng Des Sel 2007; 20: 521-3.
55. Chou PY, Fasman GD. Conformational Parameters for Amino-Acids in Helical, Beta-Sheet, and Random Coil Regions Calculated from Proteins. Biochemistry-Us 1974; 13: 211-22.
56. Zibaee S, Makin OS, Goedert M, Serpell LC. A simple algorithm locates beta-strands in the amyloid fibril core of alpha-synuclein, A beta, and tau using the amino acid sequence alone (vol 16, pg 906, 2007). Protein Sci 2007; 16: 906-18.
57. Conchillo-Sole O, de Groot NS, Aviles FX, Vendrell J, Daura X, Ventura S. AGGRESCAN: a server for the prediction and evaluation of hot spots of aggregation in polypeptides. BMC Bioinformatics 2007; 8: 65.
58. Bryan AW, Menke M, Cowen LJ, Lindquist SL, Berger B. BETASCAN: Probable beta-amyloids Identified by Pairwise Probabilistic Analysis. Plos Comput Biol 2009; 5: e1000333.
59. Garbuzynskiy SO, Lobanov MY, Galzitskaya OV. FoldAmyloid: a method of prediction of amyloidogenic regions from protein sequence. Bioinformatics 2010; 26: 326-32.
60. Galzitskaya OV, Garbuzynskiy SO, Lobanov MY. Prediction of amyloidogenic and disordered regions in protein chains. Plos Computational Biology 2006; 2: e177.
61. Kuhlman B, Baker D. Native protein sequences are close to optimal for their structures. Proc Natl Acad Sci U S A 2000; 97: 10383-8.
62. Thompson MJ, Sievers SA, Karanicolas J, Ivanova MI, Baker D, Eisenberg D. The 3D profile method for identifying fibril-forming segments of proteins. Proc Natl Acad Sci U S A 2006; 103: 4074-8.
63. Goldschmidt L, Teng PK, Riek R, Eisenberg D. Identifying the amylome, proteins capable of forming amyloid-like fibrils. Proc Natl Acad Sci U S A 2010; 107: 3487-92.
64. Maurer-Stroh S, Debulpaep M, Kuemmerer N, Lopez de la PM, Martins IC, Reumers J, et al. Exploring the sequence determinants of amyloid structure using position-specific scoring matrices. Nat Methods 2010; 7: 237-42.
65. Kumar S, Sarkar A, Sundar D. Controlling aggregation propensity in A53T mutant of alpha-synuclein causing Parkinson's disease. Biochem Bioph Res Co 2009; 387: 305-9.
66. Giasson BI, Murray IVJ, Trojanowski JQ, Lee VMY. A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J Biol Chem 2001; 276: 2380-6.
67. Ramirez-Alvarado M, Merkel JS, Regan L. A systematic exploration of the influence of the protein stability on amyloid fibril formation in vitro. P Natl Acad Sci USA 2000; 97: 8979-84.
68. Nguyen HD, Hall CK. Kinetics of fibril formation by polyalanine peptides. J Biol Chem 2005; 280: 9074-82.
69. Harris SA, Laughton CA, Liverpool TB. Mapping the phase diagram of the writhe of DNA nanocircles using atomistic molecular dynamics simulations. Nucleic Acids Res 2008; 36: 21-9.
70. Berryman JT, Radford SE, Harris SA. Thermodynamic description of polymorphism in Q- and N-rich peptide aggregates revealed by atomistic simulation. Biophys J 2009; 97: 1-11.
71. Taylor JP, Hardy J, Fischbeck KH. Toxic proteins in neurodegenerative disease. Science 2002; 296: 1991-5.
72. Goate A, Chartier-Harlin MC, Mullan M, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991; 349: 704-6.
73. Levy-Lahad E, Wasco W, Poorkaj P, et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 1995; 269: 973-7.
74. Sherrington R, Rogaev EI, Liang Y, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 1995; 375: 754-60.
75. Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 1996; 2: 864-70.
76. Citron M. Strategies for disease modification in Alzheimer's disease. Nat Rev Neurosci 2004; 5: 677-85.
77. McClellan AJ, Frydman J. Molecular chaperones and the art of recognizing a lost cause. Nat Cell Biol 2001; 3: E51-E3.
78. Kopito RR. Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol 2000; 10: 524-30.
79. Ravikumar B, Vacher C, Berger Z, et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet 2004; 36: 585-95.
80. Tanaka M, Kim YM, Lee G, Junn E, Iwatsubo T, Mouradian MM. Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective. J Biol Chem 2004; 279: 4625-31.
81. Tanaka M, Machida Y, Niu SY, et al. Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. Nat Med 2004; 10: 148-54.
82. Bohrmann B, Adrian M, Dubochet J, et al. Self-assembly of beta-amyloid 42 is retarded by small molecular ligands at the stage of structural intermediates. J Struct Biol 2000; 130: 232-46.
83. Wood SJ, MacKenzie L, Maleeff B, Hurle MR, Wetzel R. Selective inhibition of A beta fibril formation. J Biol Chem 1996; 271: 4086-92.
84. Reixach N, Crooks E, Ostresh JM, Houghten RA, Blondelle SE. Inhibition of beta-amyloid-induced neurotoxicity by imidazopyridoindoles derived from a synthetic combinatorial library. J Struct Biol 2000; 130: 247-58.
85. Lee EN, Cho HJ, Lee CH, Lee D, Chung KC, Paik SR. Phthalocyanine tetrasulfonates affect the amyloid formation and cytotoxicity of alpha-synuclein. Biochemistry 2004; 43: 3704-15.
86. Cordeiro Y, Lima LM, Gomes MP, Foguel D, Silva JL. Modulation of prion protein oligomerization, aggregation, and beta-sheet conversion by 4,4'-dianilino-1,1'-binaphthyl-5,5'-sulfonate (bis-ANS). J Biol Chem 2004; 279: 5346-52.
87. Davidson BL, Paulson HL. Molecular medicine for the brain: silencing of disease genes with RNA interference. Lancet Neurol 2004; 3: 145-9.
88. Mattson MP, Chan SL. Good and bad amyloid antibodies. Science 2003; 301: 1847-9.
89. Weiner HL, Selkoe DJ. Inflammation and therapeutic vaccination in CNS diseases. Nature 2002; 420: 879-84.
90. Monsonego A, Weiner HL. Immunotherapeutic approaches to Alzheimer's disease. Science 2003; 302: 834-8.
91. Citron M. Alzheimer's disease: treatments in discovery and development. Nat Neurosci 2002; 5: 1055-7.